Basic and Clinical Research of p53 Gene Therapy for Human Cancer
Basic and Clinical Research of p53 Gene Therapy for Human Cancer
批准号:
08671529
负责人:
INOUE Fumiyuki
金额:
$1.41万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (C)
财政年份:
1996
资助国家:
日本
项目状态:
已结题
起止时间:
1996 至 1997
中文摘要
恶性肿瘤的生长和进展需要血管生成。最近的研究表明,遗传改变可能伴随着血管生成表型的获得。肿瘤抑制基因p53在人类癌症中最常突变,并且也已知是多种基因的转录调节因子。在这里,我们研究了野生型p53基因转移对人非小细胞肺癌细胞系的抗血管生成作用。使用重组腺病毒载体(Ad 5CMVp 53)用野生型p53基因转导突变型p53表达H226 Br NSCLC细胞,并应用半定量逆转录聚合酶链反应检测血管生成和/或抗血管生成因子的mRNA表达改变。然后使用膜扩散室系统在nu/nu小鼠中皮下移植进行Ad 5CMVp 53感染的细胞的体内新血管形成测定。我们还通过将细胞混合物皮下接种到nu/nu小鼠体内来评估Ad 5CMVp 53感染的H226 Br细胞对未转导的肿瘤细胞的影响。Ad 5CMVp 53感染显著抑制血管生成因子血管内皮生长因子(VEGF)的表达,并增加一种新的抗血管生成因子脑特异性血管生成抑制因子1(BAI 1)的表达,导致体内新生血管减少。混合实验表明,用野生型p53基因转导的肿瘤细胞抑制邻近的非转导细胞的体内肿瘤生长。我们的数据表明,表达野生型p53基因的重组腺病毒是抗血管生成的,这可以部分解释的旁观者效应诱导的野生型p53基因转移对邻近的肿瘤细胞的机制。
英文摘要
Angiogenesis is required for the growth and progression of malignancies. Recent studies have demonstrated that genetic alterations may accompany acquisition of the angiogenic phenotype. The tumor suppressor p53 gene is most frequently mutated in human cancers and is also known to be a transcriptional regulator of a variety of genes. Here we investigated the antiangiogenic effect of the wild-type p53 gene transfer on a human non-small-cell lung cancer cell line. Mutant p53-expressing H226Br NSCLC cells were transduced with the wild-type p53 gene using a recombinant adenoviral vector (Ad5CMVp53) and applied to semi-quantitative reverse transcription-polymerase chain reactions to detect altered mRNA expression of angiogenic and/or antiangiogenic factors. In vivo neovascularization assay of Ad5CMVp53-infected cells was then performed using a membrane-diffusion chamber system subcutaneously transplanted in nu/nu mice. We also evaluated the effect of Ad5CMVp53-infected H226Br cells on nontransduced tumor cells in vivo by subcutaneously inoculating mixture of cells into nu/nu mice. Ad5CMVp53 infection markedly inhibited the expression of an angiogenic factor, vascular endothelial growth factor (VEGF), and increased the expression of a novel antiangiogenic factor, brain-specific angiogenesis inhibitor 1 (BAI1), resulting in the reduced neovascularization in vivo. Mixing experiments showed that tumor cells transduced with the wild-type p53 gene inhibited the in vivo tumor growth of adjacent nontransduced cells. Our data suggest that a recombinant adenovirus expressing the wild-type p53 gene is antiangiogenic, which may explain in part the mechanism of the bystander effect induced by the wild-type p53 gene transfer on adjacent tumor cells.
期刊论文(8)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
藤原俊義: "癌抑制遺伝子p53発現ウイルスベクターによる癌の遺伝子治療." Human Cell. 9. 25-30 (1996)
Toshiyoshi Fujiwara:“使用表达肿瘤抑制基因 p53 的病毒载体进行癌症基因治疗。”Human Cell。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
藤原俊義: "胃癌・大腸癌のDNA障害性抗腫瘍治療における変異型p53発現の意義." 癌と化学療法. 23. 1081-1083 (1996)
Toshiyoshi Fujiwara:“突变型 p53 表达在胃癌和结直肠癌 DNA 损伤性抗肿瘤治疗中的意义。” 23. 1081-1083 (1996)
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
Nishizaki M: "Antiangiogenic effect of recombinant adenovirus expressing the wild-type p53 gene: proposed mechanism for bystander effect." Clinical Cancer Research. in press. (1999)
Nishizaki M:“表达野生型 p53 基因的重组腺病毒的抗血管生成作用:提出的旁观者效应机制。”
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
Bouvet, M., Ellis, L.M., Nishizaki, M., Fujiwara, T., Liu, W., Bucana, C.D., Fang, B,Lee, J.J., Roth, J.A.: "Adenovirus-mediated Wild-type p53 gene transfer downregulates vascular endotherial growth factor expression and inhibits angiogenesis in human col
Bouvet, M.、Ellis, L.M.、Nishizaki, M.、Fujiwara, T.、Liu, W.、Bucana, C.D.、Fang, B、Lee, J.J.、Roth, J.A.:“腺病毒介导的野生型 p53 基因转移
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
Hamada,M.: "p53 is a potent determinant of chemosensitivity and radiosensitivity in human gastric and rectal cancers." J.Cancer Res.Clin.Oncol.122. 360-365 (1996)
Hamada,M.:“p53 是人类胃癌和直肠癌化学敏感性和放射敏感性的有效决定因素。”
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
共 7 条
海外基金